A feasibility and tolerability study of lithium in Alzheimer's disease.
about
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNSTherapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorderA new look at an old drug: neuroprotective effects and therapeutic potentials of lithium saltsGlycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and ImagingNew pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugsTherapeutic and diagnostic challenges for frontotemporal dementiaNFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapyLithium suppresses Aβ pathology by inhibiting translation in an adult Drosophila model of Alzheimer's diseaseTargeting protein kinases in central nervous system disordersNeuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disordersLong-term lithium treatment reduces glucose metabolism in the cerebellum and hippocampus of nondemented older adults: an [¹⁸F]FDG-PET studyTargeting Abeta and tau in Alzheimer's disease, an early interim reportDoes lithium prevent Alzheimer's disease?Using lithium as a neuroprotective agent in patients with cancerEndocrine, metabolic, nutritional, and toxic disorders leading to dementia.Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependentGSK-3 in Neurodegenerative Diseases.Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disordersLonger lithium exposure is associated with better white matter integrity in older adults with bipolar disorder.Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders.The importance of tau phosphorylation for neurodegenerative diseasesLithium down-regulates histone deacetylase 1 (HDAC1) and induces degradation of mutant huntingtin.New treatment strategies for Alzheimer's disease: is there a hope?Therapeutic strategies for tau mediated neurodegeneration.Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.Tau as a therapeutic target for Alzheimer's diseaseModulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies.GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration.New and emerging treatments for Alzheimer's disease.New and emerging treatments for Alzheimer's disease.Wnt and lithium: a common destiny in the therapy of nervous system pathologies?Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.Alzheimer disease therapy--moving from amyloid-β to tau.GSK-3β, a pivotal kinase in Alzheimer disease.Standard and trace-dose lithium: a systematic review of dementia prevention and other behavioral benefits.Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders.Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.Lithium suppression of tau induces brain iron accumulation and neurodegeneration.The Role of α-Synuclein and LRRK2 in Tau Phosphorylation.
P2860
Q21129334-D0D410E9-8B9C-4B62-A0E0-4F72BE616D38Q24626017-D03183F8-B262-4CE0-96A5-4A4C254D9B8AQ26741164-22074CC2-07E5-4DB6-8DFB-29672613E1F4Q26768475-3D11BED3-6FD5-489B-9F87-F4C61862BF93Q26866006-3EA4596E-3E10-4104-A5BF-035256B88F79Q26998919-D326D4A9-8E45-4169-8085-AB76437B67D9Q28586033-4DCC45D3-90D1-4799-BB6B-54DD7A2A5D9BQ29036305-BEE4DA5F-72E7-483F-9C78-0249D92414F4Q33671660-5FBE2A53-F097-4488-9BFF-020B3A8F5E21Q33777958-592D2B4F-6B2B-40C6-A691-F722A544C47FQ33777999-C646B81D-AF7D-46AD-A784-E84AAB5D292BQ33829008-09760130-F672-4775-A3CA-EB5525814F6AQ34268138-DE933F05-8CC6-42DC-96D8-7C11E90FADB6Q34465844-1ABDF30C-A348-409A-804C-1750919B7300Q34574924-E056F339-C073-4546-97BE-78D39767B4D4Q34936432-AEB674A0-EA6C-4D2C-A409-0AB557DC810DQ35001040-5BFB509D-215E-4BD0-9C2F-1FCEBA618D39Q35197096-F4E30BE7-9532-483D-9FB3-C7210A88F692Q35217858-F079B6A4-70A0-4B07-B556-56E8AF4D05CEQ36769080-E94A63BF-669A-4BFA-9678-9A7616431C7AQ36968220-8C1B815A-F94A-48B3-9245-2ED670AFDAA7Q37368725-C0E5D843-9632-4127-BC53-ADB1D2EA39D4Q37403383-B76B3E32-51BE-40D5-9DEC-9E1AA78DDCA4Q37550818-649E6AA5-2093-4FB9-92E7-5105D8A6D0C6Q37810697-85BA5B86-72EE-4FCF-AA33-71CB584B9F3DQ37890451-130E484D-D834-45BB-BDB8-99948123A831Q37946881-664C5BD2-C03B-41B0-8894-F45AABA1DA8BQ37959957-FCD2796D-937D-45CC-8734-082384BB6C50Q37996072-F99808C2-3A47-479B-8DF1-344D3D3CF9D4Q38006979-800EAED6-1B52-46E9-B7E7-F0954CEB1C65Q38113139-4EAC740A-765F-4A31-AF3E-E7A1A7A7578EQ38126701-9430632E-D1DB-4892-BE5A-949C73308DA0Q38161786-3A1F30DD-3817-49DA-8CE3-72EED04C4932Q38218085-8E86BF11-2198-480F-AD6E-0D8CF2BEA4DAQ38219564-ED3388E1-61FA-4515-9FC2-E7AE981AA522Q38253573-4F7FC693-8946-4F80-BFC6-F2D90307E9EFQ38266162-473E305D-E798-4962-8282-26261AD910C5Q38299414-4CA0A09D-816A-46CB-9BDC-08CF40185ED5Q38412707-CFD4494C-4801-4C2A-BC07-DB9809C45A63Q38482479-FA3C78DB-5632-4FD3-AA29-4C5D34B20BF8
P2860
A feasibility and tolerability study of lithium in Alzheimer's disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
A feasibility and tolerability study of lithium in Alzheimer's disease.
@en
A feasibility and tolerability study of lithium in Alzheimer's disease.
@nl
type
label
A feasibility and tolerability study of lithium in Alzheimer's disease.
@en
A feasibility and tolerability study of lithium in Alzheimer's disease.
@nl
prefLabel
A feasibility and tolerability study of lithium in Alzheimer's disease.
@en
A feasibility and tolerability study of lithium in Alzheimer's disease.
@nl
P2093
P2860
P356
P1476
A feasibility and tolerability study of lithium in Alzheimer's disease.
@en
P2093
Alastair Macdonald
Andrea Higgins
Kate Briggs
Michaela Poppe
P2860
P304
P356
10.1002/GPS.1964
P407
P577
2008-07-01T00:00:00Z